LYL1 and cancer: Sunitinib‐related pathways (hsa04370: VEGF signaling pathway; hsa04010: MAPK signaling pathway; and hsa05200: pathways in cancer) were analyzed by GSEA, which indicated CRYBB1 (p‐value; Pathways in cancer: 1.57e−04; MAPK signaling pathway: 2.65e−03; VEGF signaling pathway: 0.018) and LYL1 (p‐value; Pathways in cancer: 5.22e−07; MAPK signaling pathway: 7.89e−07; VEGF signaling pathway: 1.80e−03) were implicated in all sunitinib‐related pathways.